Home self-administration of vaginal misoprostol for medical abortion at 50-63 days compared with gestation of below 50 days

被引:39
|
作者
Kallner, H. Kopp [1 ]
Fiala, C. [2 ]
Stephansson, O. [1 ,3 ]
Gemzell-Danielsson, K. [1 ]
机构
[1] Karolinska Univ Hosp, Karolinska Inst, Dept Womens & Childrens Hlth, Div Obstet & Gynaecol, S-17176 Stockholm, Sweden
[2] Gynmed Clin, A-1150 Vienna, Austria
[3] Karolinska Univ Hosp, Karolinska Inst, Dept Med, Clin Epidemiol Unit, S-17176 Stockholm, Sweden
基金
瑞典研究理事会;
关键词
mifepristone; home administration; medical abortion; termination of pregnancy; acceptability; MIFEPRISTONE; ACCEPTABILITY; COMBINATION; PREGNANCY; REGIMEN; TRIAL;
D O I
10.1093/humrep/deq037
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Home use of misoprostol for termination of pregnancy is still controversial in many countries. Acceptability of home use of misoprostol has been investigated in pregnancies below 49 days gestation. In this study, we aimed to assess efficacy, feasibility and acceptability of home use of vaginal misoprostol for medical termination of pregnancy at 50-63 days compared with gestation of below 50 days among women who chose to administer misoprostol at home. In this prospective study, mifepristone 200 mg was given in hospital under nursing supervision in the university hospital outpatient family planning clinic. Women self-administered misoprostol 800 mu g vaginally 36-48 h later at home. Follow-up was 2 weeks later. Women with gestation of 50-63 days on the day of mifepristone administration were compared with women with gestation of below 50 days. Efficacy and feasibility were assessed by review of patient records and questionnaires. Acceptability was assessed using questionnaires where women reported on future choice of abortion method were they to have another abortion. Among the 2992 women who had a medical abortion during the study period, 395 women chose to administer misoprostol at home and were included in the study. A total of 203 women were below 50 days gestation and 192 were between 50 and 63 days gestation. Efficacy was 97.5% and did not differ between the groups. Surgical intervention was needed in 10 patients, of whom four were in the lower gestational band (P = 0.36). No serious adverse events or blood transfusions were reported. Preference for home administration of misoprostol, were they to have another induced abortion in the future, was high, 92.3 and 86.6% respectively, and did not differ between the groups (P = 0.097). Need for extra analgesia significantly influenced women's experiences in both gestational groups. Medical abortion with mifepristone followed by home administration of vaginal misoprostol is safe and highly acceptable also to women with gestational length of 50-63 days as compared with shorter gestations. Efficacy, acceptability and preference for future place of administration of misoprostol, were women to have another abortion, did not differ between women with gestation below 50 days or between 50 and 63 days.
引用
收藏
页码:1153 / 1157
页数:5
相关论文
共 50 条
  • [41] A randomized clinical trial comparing the short-term side effects of sublingual and buccal routes of misoprostol administration for medical abortions up to 63 days' gestation
    Chai, Joyce
    Wong, Ching Yin Grace
    Ho, Pak Chung
    CONTRACEPTION, 2013, 87 (04) : 480 - 485
  • [42] MISOPROSTOL - A LIFE SAVER FOR WOMEN. THE EXPERIENCE OF WOMEN AND THE ACTIVISTS WITH SELF-ADMINISTRATION OF MISOPROSTOL FOR MEDICAL ABORTION AND POSTPARTUM HAEMORRHAGE PREVENTION
    Gomperts, Rebecca
    Jelinska, Kinga
    Schellekens, Marlies
    JOURNAL OF SEXUAL MEDICINE, 2013, 10 : 328 - 328
  • [43] Two prophylactic medication approaches in addition to a pain control regimen for early medical abortion < 63 days' gestation with mifepristone and misoprostol: study protocol for a randomized, controlled trial
    Dragoman, Monica V.
    Grossman, Daniel
    Kapp, Nathalie
    Nguyen My Huong
    Habib, Ndema
    Duong Lan Dung
    Tamang, Anand
    REPRODUCTIVE HEALTH, 2016, 13 : 1 - 10
  • [44] Two-pill regimens of misoprostol after mifepristone medical abortion through 63 days' gestational age: a randomized controlled trial of sublingual and oral misoprostol
    Raghavan, Sheila
    Comendant, Rodica
    Digol, Irena
    Ungureanu, Sergiu
    Friptu, Valentin
    Bracken, Hillary
    Winikoff, Beverly
    CONTRACEPTION, 2009, 79 (02) : 84 - 90
  • [45] Comparison of 400 mcg buccal and 400 mcg sublingual misoprostol after mifepristone medical abortion through 63 days' LMP a randomized controlled trial
    Raghavan, Sheila
    Comendant, Rodica
    Digol, Irena
    Ungureanu, Sergiu
    Dondiuc, Iurie
    Turcanu, Steliana
    Winikoff, Beverly
    CONTRACEPTION, 2010, 82 (06) : 513 - 519
  • [46] Expanding a woman's options to include home use of misoprostol for medical abortion up until 76 days: an observational study of efficacy and safety
    Larsson, Amanda
    Ronnberg, Ann-Kristin M.
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2019, 98 (06) : 747 - 752
  • [47] Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion: A randomized trial (vol 284, pg 1948, 2000)
    Lader, L
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 284 (20): : 2597 - 2597
  • [48] ACCEPTABILITY OF AN OUTPATIENT REGIMEN OF MEDICAL ABORTION WITH MIFEPRISTONE AND 800 MCG MISOPROSTOL ADMINISTERED BUCCALLY OR SUBLINGUALLY AT 71-84 DAYS OF GESTATION: A SERIES OF EXPLORATORY STUDIES
    Abbas, D.
    Blum, J.
    Ngoc, N.
    Winikoff, B.
    CONTRACEPTION, 2014, 89 (05) : 480 - 480
  • [49] Simultaneous compared to interval administration of mifepristone and misoprostol for medical abortion up to 10+0 weeks' gestation: a systematic review with meta-analyses
    Schmidt-Hansen, Mia
    Lord, Jonathan
    Hasler, Elise
    Cameron, Sharon
    BMJ SEXUAL & REPRODUCTIVE HEALTH, 2020, 46 (04) : 270 - 278
  • [50] A repeat dose of misoprostol 800 mcg following mifepristone for outpatient medical abortion at 64-70 and 71-77 days of gestation: A retrospective chart review
    Dzuba, Ilana G.
    Castillo, Philicia W.
    Bousieguez, Manuel
    Lugo Hernandez, Elba Margarita
    Castaneda Vivar, Jose Juan
    Sanhueza Smith, Patricio
    CONTRACEPTION, 2020, 102 (02) : 104 - 108